Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 10,218 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 10,218 shares of the company’s stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Benjamin Hohl also recently made the following trade(s):

• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $34,937.70.
• On Friday, September 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50.
• On Monday, September 30th, Benjamin Hohl sold 2,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.33, for a total transaction of $50,660.00.
• On Tuesday, August 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.54, for a total transaction of $95,795.00.
• On Wednesday, July 31st, Benjamin Hohl sold 991 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.53, for a total value of $27,282.23.
• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $26.68, for a total value of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.07, for a total value of $75,210.00.

Enliven Therapeutics Stock Performance

Shares of NASDAQ:ELVN traded up $0.56 during midday trading on Tuesday, reaching $28.01. The company had a trading volume of 174,035 shares, compared to its average volume of 261,678. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $28.51. The company has a fifty day simple moving average of $23.22 and a two-hundred day simple moving average of $22.08. The firm has a market cap of $1.32 billion, a price-to-earnings ratio of -14.51 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. Analysts expect that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ELVN shares. Robert W. Baird started coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock. Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research report on Tuesday, October 1st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its stake in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock worth $140,000 after purchasing an additional 3,189 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics in the first quarter valued at approximately $167,000. Baker BROS. Advisors LP purchased a new stake in shares of Enliven Therapeutics during the first quarter worth $2,020,000. Blackstone Inc. acquired a new position in Enliven Therapeutics in the first quarter valued at approximately $443,000. Finally, Janus Henderson Group PLC boosted its holdings in shares of Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after acquiring an additional 305,397 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.